Ann: ResApp Receives CE Mark for ResAppDx-EU, page-224

From the July 1 announcement...



“Demonstrating the accuracy of our OSA detection algorithms in the home setting will be an
important milestone in the development of a highly-scalable, accurate and easy-to-use screening
test for OSA,” said Tony Keating, CEO and Managing Director of ResApp. “Screening of OSA today
relies mostly on questionnaire-based screening tools, which in a study recently published in the
Medical Journal of Australia were found to have a sensitivity as low as 36-51%, meaning that a
large portion of people with clinically relevant OSA are missed. This highlights the need for a more
accurate screening tool. The recent inclusion of these screening questionnaires into the
requirements for Medicare reimbursement of sleep testing has impacted recruitment, however
we are now close to finalising recruitment and are looking forward to releasing results from the
study during the third quarter.”


OSA completed study next?